Sirtuin 2 enhances allergic asthmatic inflammation

Yong Gyu Lee, …, John W. Christman, Megan N. Ballinger


Allergic eosinophilic asthma is a chronic condition causing airway remodeling resulting in lung dysfunction. We observed that expression of Sirtuin 2 (Sirt2), a histone deacetylase, regulates the recruitment of eosinophils after sensitization and challenge with a triple-antigen: dust mite, ragweed, and Aspergillus fumigatus (DRA). Our data demonstrate that IL-4 regulates the expression of Sirt2 isoform 3/5. Pharmacological inhibition of Sirt2 by AGK2 resulted in diminished cellular recruitment, decreased CCL17/TARC, and reduced goblet cell hyperplasia. YM1 and Fizz1 expression was reduced in AGK2-treated, IL-4-stimulated lung macrophages in vitro as well as in lung macrophages from AGK2-DRA challenged mice. Conversely, overexpression of Sirt2 resulted in increased cellular recruitment, CCL17 production, and goblet cell hyperplasia following DRA challenge. Sirt2 isoform 3/5 was upregulated in primary human alveolar macrophages following IL-4 and AGK2 treatment resulted in reduced CCL17 and markers of alternative activation. These gain-of-function and loss-of-function studies indicate that Sirt2 could be developed as a treatment for eosinophilic asthma.

Find the latest version:

http://jci.me/124710/pdf
Sirtuin 2 enhances allergic asthmatic inflammation

Yong Gyu Lee¹, Brenda F. Reader¹, Derrick Herman¹, Adam Streicher¹, Joshua A. Englert¹,
Mathias Ziegler², Sangwoon Chung¹, Manjula Karpurapu¹, Gye Young Park³,
John W. Christman¹ and Megan N. Ballinger¹

¹Pulmonary, Critical Care and Sleep Medicine, Ohio State University Wexner Medical Center, Davis Heart
and Lung Research Institute, Columbus, Ohio 43210

²Department of Molecular Biology, University of Bergen, Postbox 7803, 5020 Bergen, Norway.

³Pulmonary, Critical Care and Sleep Medicine, University of Illinois at Chicago, Chicago, Illinois

Key Words: monocyte/macrophage, eosinophils, lung, chemokines

COI statement: The authors have declared that no conflict of interest exists.

*Corresponding Authors

Megan N. Ballinger PhD
Pulmonary, Critical Care and Sleep Medicine,
The Ohio State University Wexner Medical Center,
Davis Heart and Lung Research Institute,
Columbus, Ohio 43210
Phone: 614-292-6578 Fax: 614-293-4799
Megan.Ballinger@osumc.edu

John W. Christman MD
Pulmonary, Critical Care and Sleep Medicine,
The Ohio State University Wexner Medical Center,
Davis Heart and Lung Research Institute,
Columbus, Ohio 43210
Phone: 614-247-7804 Fax: 614-293-4799
John.Christman@osumc.edu

This work was supported by grants from the National Institutes of Health (R01HL075557, R01HL137224,
K08GM102695, and 5R01HL126852 from J.W.C, J.A.E. and G.Y.P), American Heart Association/SDG
grant (M.N.B and M.K.), American Lung Association (S.C) and the American Thoracic Society Research
Foundation (J.A.E. and M.N.B).
Abstract:

Allergic eosinophilic asthma is a chronic condition causing airway remodeling resulting in lung dysfunction. We observed that expression of Sirtuin 2 (Sirt2), a histone deacetylase, regulates the recruitment of eosinophils after sensitization and challenge with a triple-antigen: dust mite, ragweed and Aspergillus fumigatus (DRA). Our data demonstrate that IL-4 regulates the expression of Sirt2 isoform 3/5. Pharmacological inhibition of Sirt2 by AGK2 resulted in diminished cellular recruitment, decreased CCL17/TARC, and reduced goblet cell hyperplasia. YM1 and Fizz1 expression was reduced in AGK2-treated, IL-4-stimulated lung macrophages in vitro as well as in lung macrophages from AGK2-DRA challenged mice. Conversely, overexpression of Sirt2 resulted in increased cellular recruitment, CCL17 production, and goblet cell hyperplasia following DRA challenge. Sirt2 isoform 3/5 was upregulated in primary human alveolar macrophages following IL-4 and AGK2 treatment resulted in reduced CCL17 and markers of alternative activation. These gain-of-function and loss-of-function studies indicate that Sirt2 could be developed as a treatment for eosinophilic asthma.
Introduction:

Macrophages are the most abundant immune effector leukocytes found in airways and the parenchyma of the non-inflamed lung. These cells play an essential role in maintaining homeostasis and protecting against pathogenic and environmental insults. In order to accomplish these important functions, macrophages are differentially activated in response to their milieu and external stimuli. Traditionally, macrophages have been characterized based on their cytokine production profile. Pro-inflammatory or M1 macrophages are generated in the presence of IFN-γ or lipopolysaccharide (LPS). Conversely, pro-asthmatic or M2 macrophages are alternatively activated in response to stimulation by the TH2 cytokines IL-4 and/or IL-13. These differential activation patterns do not reflect terminal differentiation or maturation processes; rather, they represent how macrophages respond to their environment by expressing distinct gene profiles and functional capabilities.

Our work and that of other groups has established a link between lung macrophages and type 2 eosinophilic allergic airway inflammation and airway remodeling in the setting of allergic asthma. Based on these published data, we hypothesized that the TH2 cytokines IL-4 and/or IL-13 activate macrophages to drive type 2-inflammation and immunity. While much of the extant literature has examined the immunoregulatory function of pulmonary macrophages in asthma, the mechanisms that govern the activation of macrophages and their gene expression are still emerging. Previous work from our group has identified transcription factors responsible for macrophage activation during lung injury and inflammation. We have shown that macrophage activation is dependent on the “master myeloid” transcription factor, PU.1. Other work has demonstrated an important role for the transcription factors STAT6, interferon regulatory factor (IRF) 4 and Krüppel-like factor 4 (KLF4) in promoting alternatively activated, pro-asthmatic macrophages. Though transcriptional control of macrophage polarization is the subject of intense investigation, it is thought that the mechanism by which these cells are activated involve combinatorial interactions among transcriptional regulatory proteins, microRNA, and epigenetic mechanisms.
Sirtuins were initially described as transcriptional-silencing histone deacetylases in yeast (16). In mammals, seven sirtuins (Sirt1-7) all share a similar catalytic domain and use NAD+ as a co-substrate, but they all have different substrate affinities and subcellular compartmentalization. Although initially identified as deacetylases, sirtuins are now known to regulate a variety of enzymatic activities and biologic processes including: aging, transcription, apoptosis, inflammation, and oxidative stress (16). Class I sirtuins include Sirt1, Sirt2, and Sirt3. Previous work has demonstrated that Sirt2 deacetylates a variety of cytoplasmic and nuclear proteins and is a key modulator of cellular processes including cell cycle, metabolic homeostasis, apoptosis, and antioxidant defense mechanisms (17-21). For example, during acute inflammation during experimental colitis, Sirt2 has been shown to regulate macrophage polarization. Macrophages isolated from Sirt2-deficient mice had hyperacetylation on the p65 (Rel A) subunit of NF-κB which correlated with elevated production of pro-inflammatory cytokines (22).

There are several different isoforms of Sirt2 found in both human and mouse samples. Previous work has determined that these isoforms result from alternative splicing mechanisms rather than protein degradation (23-25). Sirt2 isoform 1 and 2 are most similar and are localized in the cytoplasm under resting conditions (23, 24). It has been predicted that Sirt2 isoform 2 could be generated from isoform 1, which may explain differences in isoform expression in different tissue samples. The third Sirt2 isoform has been called isoform 3 in murine studies and isoform 5 in human studies (24). The Sirt2 isoform 3/5 is thought to be primarily localized to the nucleus, since it lacks exon 2-4 and the nuclear export sequence. Although initial reports have determined Sirt2 isoform 5 to be catalytically inactive, its function has yet to be determined.

In this manuscript, we have determined that in vitro treatment of mouse and human macrophages with IL-4 results in elevated gene expression of Sirt2 isoform 3/5. We also observed that pharmacologic ablation of Sirt2 attenuates and genetic overexpression of Sirt2 exaggerates the allergic asthmatic phenotype. These lost and gain-of-function studies indicate that Sirt2 has an important role in regulating allergic asthmatic response that can be targeted by pharmacologic intervention.
Results:

*Genetic manipulation of Sirt2 expression regulates allergic inflammation in a murine model of allergen challenge.*

Previous work demonstrated that Sirt2 reduces M2-associated inflammation (22). To determine the role of Sirt2 in regulating allergic inflammation, we sensitized then challenged wild-type (WT), Sirt2-deficient (KO), and Sirt2 overexpressing transgenic (Tg) mice with three combined allergens including dust mite, ragweed and *Aspergillus fumigatus* (DRA) extracts (Supplemental Figure 1A) as previously reported (7, 12). After challenge, there was a doubling of the total BAL cells in the Sirt2 Tg DRA-challenged mice and approximately a 50% reduction in the total BAL cells in the Sirt2 KO DRA-challenged mice compared to WT mice (Figure 1A). The majority of the cells in all mice, regardless of Sirt2 expression, were eosinophils (Figure 1A). Lung histology demonstrated enhanced PAS staining and goblet cell hyperplasia in the Tg mice and reduced staining in the Sirt2 KO mice (Figure 1B). Airway hyper-reactivity (AHR) was assessed in response to nebulized methacholine in WT and Tg DRA-challenged mice. The Tg mice showed a significant increase in airway resistance compared to the WT mice (Figure 1C). Cytokine array analysis demonstrated altered significant increase in CCL17/TARC in Tg BAL fluid and decreased in KO BAL fluid following DRA challenge (Supplement Figure 1B). Overall, there was elevated proinflammatory cytokines, such as IFN-γ, GM-CSF IL-1, and TNFα, and anti-inflammatory cytokines, IL-4 and IL-5, in the Sirt2 Tg and Sirt2 KO compared to WT mice. Additionally, there was a decrease in the MCP-1 expression in Sirt2 KO compared to Sirt2 WT and Sirt2 Tg. Since the effects of CCL17 vary across the different groups, these findings were validated by ELISA, which confirmed significant differences in CCL17 based on Sirt2 overexpression or deficiency (Figure 1D). Interestingly, overexpression of Sirt2 did not change CCR4, CCL17 receptor, on macrophages following DRA challenge (CCR4 expression from WT DRA-challenge 3.9±1.8-fold increased and Sirt2 Tg-challenged
4.5±1.6-fold increase). These gain- and loss-of-function data in Tg and KO mice, respectively, indicate that Sirt2 is an important regulator of allergic inflammation.

Several different isoforms of Sirt2 have been described previously (18, 24). We sought to determine which isoform was driving the development of allergic airway inflammation in our model. To do this, we isolated lung macrophages via collagenase digestion from WT and Tg DRA-challenged mice and measured the expression of Sirt2 isoforms at the time of isolation or in the presence or absence of IL-4 for 48 hrs. In WT lung macrophages, \textit{in vitro} incubation for 48 hrs resulted in a decrease in Sirt2 isoform 1 and 2. Interestingly, IL-4 stimulated WT lung macrophages had elevated Sirt2 isoform 3/5 expression (Figure 1E). IL-4 stimulation of lung macrophages isolated from Sirt2 Tg mice shown no difference in expression of Sirt2 isoform 1 when compared to control cells. Incubation of lung macrophages from Sirt2 Tg mice for 48 hrs resulted in decreased Sirt2 isoform 2 and an increase in Sirt2 isoform 3/5 expression (Figure 1E). This appears to be a lung-specific effect, because bone marrow-derived macrophages (BMDMs) and peritoneal macrophages (PMs) isolated from WT mice showed similar expression patterns of Sirt2 isoform 1, 2 and 3/5-4 after overnight IL-4 stimulation (Supplemental Figure 2A).

To verify that the bands on the Western blot corresponded to their respective Sirt2 isoforms, we obtained His-tagged plasmids for Sirt2 isoform 1 and Sirt2 isoform 5 (24). These plasmids were transfected into HEK293 cells and expression of the specific isoforms were assessed by Western blot analysis using the Sirt2 antibody as well as an antibody against the histidine tag. Using the Sirt2 antibody a band was found at ~40 KD from the Sirt2 isoform 1 plasmid and possibly a faint band for Sirt2 isoform 2. At 35 KD there was a single band from the Sirt2 isoform 3/5 (Supplemental Figure 2B). The same banding pattern was observed when using the histidine specific antibody.

The mechanism by which Sirt2 isoform 3/5 is generated was examined in lung macrophages isolated from WT mice that were stimulated with IL-4 \textit{in vitro} in the presence or absence of protein synthesis and degradation inhibitors (Supplemental Figure 2C-D). IL-4 treatment of WT lung macrophages upregulated Sirt2 isoform 5 (Supplemental Figure 2C-D). Incubation of lung macrophages
with MG-132, a proteasome inhibitor, did not change Sirt2 isoform 1, 2 or 3/5 protein levels at baseline. However, there was a decrease in Sirt2 isoform 3/5 in IL-4-stimulated lung macrophages that were treated with 0.5 μM MG-132 for 24 hrs (Supplemental Figure 2C). Incubation of lung macrophages with the protein synthesis inhibitor, cycloheximide (CHX), resulted in reduced Sirt2 isoform 3/5 protein expression at baseline and when stimulated with IL-4 (Supplemental Figure 2D). These data suggest that Sirt2 isoform 3/5 is generated via protein synthesis under homeostatic conditions and possibly via inhibition of proteosomal degradation and accumulated protein synthesis when stimulated.

*Pharmacologic inhibition of Sirt2 mitigates the development of allergic inflammation in a murine asthma model*

Because of the relative abundance of the different sirtuin proteins, we utilized a specific pharmacological inhibitor of Sirt2 in order to dissect compensatory changes that would occur by genetic overexpression or deficiency. Previous work has identified that AGK2 is a potent and highly selective inhibitor of Sirt2 (26). WT mice were sensitized and challenged with either saline or DRA and then treated with either AGK2 or vehicle control 30 mins prior to DRA challenge on days 12, 13, and 14 (Supplemental Figure 1A). The relative number of leukocytes was quantified in the lungs at day 15 (Figure 2A) using the flow cytometric gating strategy shown in Supplemental Figure 3. As previously demonstrated, DRA challenge resulted in a significant increase in eosinophils (CD45+CD3-SigF+Ly6G-CD11c+). Interestingly, there was also a significant increase in monocytes and interstitial macrophages (CD45+CD3-SigF-Ly6G-CD11b+), but no change in the total number of resident alveolar macrophages (CD45+CD3-Ly6G-SigF+) following DRA challenge. There was a slight increase in the total number of T cells (CD45+CD3+) and neutrophils (CD45+CD3-SigF-LyG6+CD11b+) in mice that received DRA challenge compared to saline alone.

Treatment of the saline challenged mice with AGK2 did not result in any difference in the CD45+ cells in the lung. However, DRA-challenged mice treated with AGK2 had significantly less eosinophils, monocytes/interstitial macrophages, T cells and neutrophils in their lungs compared to DRA-challenged
mice treated with vehicle. In addition, AGK2-treated DRA-challenged mice had less cellular infiltration, reduced PAS staining and goblet cell hyperplasia (Figure 2B). Furthermore, there was significantly less CCL17 in the BAL fluid of AGK2 treated DRA-challenged WT compared to vehicle treated mice (Figure 2C). These data demonstrate that pharmacological inhibition of Sirt2 reduced allergic inflammation following DRA challenge and mirror the changes seen in Sirt2 KO mice (Figure 1).

Because we observed differences in macrophage/monocyte populations in the lung following DRA challenge, we were interested in determining the activation phenotype of these cells. We measured expression of alternative activation markers Ym1 and Fizz1 in whole lung tissue from saline and DRA-challenged mice treated with AGK2 or vehicle control. DRA-challenged mice had significant increases in YM1 and Fizz1 expression; however, inhibition of Sirt2 following DRA challenge resulted in a significant reduction in Ym1 and Fizz1 expression (Figure 2D). In order to determine the role of Sirt2 in regulating macrophage activation, lung macrophages were isolated from WT mice and incubated with IL-4 and increasing doses of AGK2 in vitro. After 48 hrs, IL-4-treated macrophages showed a significant increase in the expression of CCL17, Ym1, and Fizz1 mRNA transcripts measured by qPCR (Figure 2E). There was a dose dependent decrease of alternative activation markers when treated with AGK2 in the presence of IL-4 stimulation (Figure 2E). These data suggest that the Sirt2 inhibitor AGK2 alters allergic inflammation by DRA-challenge by regulating the macrophage activation phenotype.

* Sirt2 expression in bone marrow derived cells regulates the development of allergic airway inflammation *

In order to determine the relative effects of Sirt2 expression of bone marrow-derived cells compared to structural cells, we developed a bone marrow transplantation (BMT) chimera model. Bone marrow was isolated from WT or Sirt2 overexpressing Tg mice and transplanted into lethally irradiated WT mice. In order to validate complete reconstitution of the BMT chimera model, we utilized the congenic markers to track CD45.2 donor (WT and Sirt2 Tg) and CD45.1 recipient cells. After reconstitution, the mice had approximately 95% donor (CD45.2) derived cells (Supplemental Figure 4). Interestingly, additional flow
cytometric gating determined that the remaining recipient derived cells present in the lung following irradiation and reconstitution were positive for CD3 (Supplemental Figure 4). These data demonstrate that, following BMT, the majority of the macrophages present in the lung were donor-derived.

Overexpression of Sirt2, specifically in the bone marrow compartment, resulted in a significant increase in total cells in the whole lung and BAL fluid (Figure 3A and B). There were also significantly more eosinophils in both the whole lung as well as the BAL fluid in Sirt2-Tg BMT mice compared to WT BMT mice. In addition, there was a significant increase in the number of monocytes/interstitial macrophages in the BAL fluid of Tg BMT mice compared to those who received WT BMT. Histology demonstrated increased PAS staining in Tg BMT mice compared to WT BMT (Figure 3C). There was a significant increase in CCL17 in the BAL fluid as well as whole lung of Tg BMT mice compared to WT BMT mice (Figure 3D). Together, these data demonstrate that overexpression of Sirt2 only in bone marrow-derived cells enhances DRA-induced allergic inflammation resulting in increased eosinophilic infiltration and goblet cell hyperplasia in the lungs.

Adoptive transfer of Sirt2 Tg lung macrophages exacerbates allergic airway inflammation

To validate the role of macrophages in regulating the allergic inflammatory response in the lung following DRA challenge, naïve primary macrophages were isolated from WT or Sirt2 Tg mice (expressing the congenic CD45.2 marker) and adoptively transferred into CD45.1 recipient mice on day 8 (Supplemental Figure 1A). On day 15 following DRA challenge, the total number of recipient-derived cells (CD45.1) were determined by flow cytometric analysis (Supplemental Figure 4). As shown in Figure 4A, there was a significant increase in eosinophils and alveolar macrophages in the mice that received the lung macrophages isolated from Sirt2 overexpressing Tg mice compared to those receiving macrophages isolated from WT mice. Similar to the findings in the BMT experiment, histologic analysis revealed enhanced PAS staining in the CD45.1 recipient mice that received the Tg macrophages (Figure 4B). In addition, there was elevated expression of CCL17 in whole lung tissue as well as BAL
fluid in mice that received the adoptive transfer of Tg lung macrophages (Figure 4C). Finally, adoptive transfer of lung macrophages from Sirt2 overexpressing Tg mice significantly increase in the expression markers of alternative macrophage activation in whole lung tissue (Figure 4D). Together, these data demonstrate that adoptive transfer of lung macrophages that overexpress of Sirt2 enhances DRA-induced allergic airway inflammation.

*Sirt2 expression regulates CCL17 and macrophage alternative activation markers in human lung macrophages.*

Primary human alveolar macrophages were isolated via *ex vivo* lavage from donor lungs deemed not viable for transplantation. Expression of Sirt2 isoforms were measured after stimulation with macrophage polarizing cytokines (Figure 5A). Stimulation of human lung macrophages with IL-4, IL-13 or IFN gamma did not alter expression of Sirt2 isoforms 1 and 2. Interestingly, stimulation with IL-4 for 48 hrs resulted in a significant increase in Sirt2 isoform 3/5 expression (Figure 5A) similar to our findings in murine macrophages (Figure 1E). Incubation of human alveolar macrophages with IL-4 resulted in a significant increase in CCL17, Arg1 and mannose receptor C-type (MRC1) expression as measured by qPCR (Figure 5B and 5C). Inhibition of Sirt2 by AGK2 significantly reduced expression of alternatively activated macrophage markers in a dose-dependent manner. These data demonstrate that Sirt2 isoform 3/5 is an IL-4 regulated protein in human and murine macrophages that regulate the development of allergic inflammation in the lung.
Discussion:

Asthma is a major health concern, but despite increasing prevalence there are relatively few new classes of therapeutics developed to treat or control this disease. Using a murine model of allergic airway inflammation, our data demonstrate that expression of Sirt2 regulates eosinophilic inflammation in response to allergen challenge. We observed a significant upregulation in Sirt2 isoform 3/5 in lung macrophages following *in vitro* IL-4 stimulation or *in vivo* DRA challenge. In addition, our data indicate that overexpression or inhibition of Sirt2 regulates expression of TARC/CCL17 and recruitment of monocytes and macrophages into the airways following allergen sensitization and challenge. We demonstrate that Sirt2 isoform 3/5 is regulated by IL-4 stimulation and protein synthesis in lung macrophages. Interestingly, this effect appears to be lung specific since there was no difference in Sirt2 isoform 3/5 expression in bone-marrow derived or peritoneal macrophages after IL-4 stimulation. Pharmacologic inhibition of Sirt2 reduced cellular recruitment, diminished CCL17 expression, and decreased expression of alternatively activated macrophage markers. Conversely, overexpression of Sirt2 using bone marrow chimeras or adoptive transfer of lung macrophages led to an exacerbated allergic response with elevated CCL17 production and enhanced goblet cell hyperplasia. Importantly, we also show that IL-4 regulates Sirt2 isoform 3/5 in human alveolar macrophages suggesting that this pathway may be relevant to human asthma. Finally, incubation of IL-4 skewed macrophages with a Sirt2 inhibitor resulted in reduced expression of CCL17 as well as macrophage markers of alternative activation. Together, these data shed light on the growing body of literature suggesting that macrophage activation plays an important role in regulating the development of allergic inflammation in asthma and identifies a novel role for Sirt2 in regulating a pro-asthmatic macrophage phenotype.

The incidence of asthma and allergy has been on the rise in the US and is of significant public health concern because of rising health care costs as well as loss of productivity and reduced quality of life. Previous work has determined that exposure to common indoor allergens, such as dust mites and those generated from animals and mold, are considered a risk factor for asthma. Previous work has demonstrated that at least half of the over 800 housing units surveyed across 75 different locations in the
US had one allergen and 45.8% of them at least 3 allergens (27). These data are reinforced by a recent study highlighting the fact that multicomponent interventions, but not single interventions, of removing indoor allergens showed improved asthma outcomes (28). In order to understand that complex interactions which occur in the setting of allergen inflammation, several groups have development multiple allergen murine models (29, 30). Our work seeks to extend these results and examine the role of macrophages in regulating the acute allergic inflammatory phenotype by using a triple antigen model. Although we acknowledge that the use of three antigens, as well as the use of alum during the sensitization phase, does complicate the system and is a limitation in current model.

Despite the fact that macrophages are the most abundant immune cell in the homeostatic lung, the role of macrophages in regulating the development of allergic inflammation has been controversial (31). Previous work done by our group and others has demonstrated that macrophages play an important role in the development of the allergic inflammatory response (7, 32-34). In contrast, other reports have suggested that these innate immune cells may only play a minor role in the development of an experimental allergic response (35, 36). One important consideration when examining the body of literature in regards to the role of macrophages in allergic inflammation is there are genetic differences between alternatively activated mouse and human macrophages (37). Another aspect is the role of other cells in regulating monocyte trafficking in response to an allergen challenge as well as macrophage differentiation and activation. We acknowledge that our study did not focus on dendritic cells or CD4 T cells and their role in producing cytokines and chemokines, but rather our work demonstrates that lung macrophages collected following DRA-challenge have a differential activation phenotype and produce altered cytokines and chemokines.

Because macrophages are a heterogeneous population of cells, the discrepancy among the conclusions in these reports may be different due to the lack of consideration of the derivation and the overall activation phenotype of the different macrophage subpopulations. Exciting new work has emerged that has begun to identify derivation markers to distinguish between embryonic and bone marrow derived macrophage subpopulations in the lung (38, 39); however, additional work is needed to fully understand
the implications of this macrophage heterogeneity and diversity in the setting of allergic inflammation. It is also important to consider that allergic asthma presents with different endotypes characterized by a predominance of eosinophils or neutrophils in the airways. These endotypes can be modeled in the laboratory by manipulating the breed of mouse, allergen, timeline or route of administration of the challenge, and macrophages may play different roles during inflammation depending on the prevalent granulocytic cell type found in the model. This current study aimed to delineate the role of macrophage activation in regulating eosinophilic allergic airway inflammation.

Our work has demonstrated an important role of Sirt2 in regulating the production of CCL17 in the setting of allergic inflammation. Chemokines, such as CCL17 and CCL22, are pivotal in regulating allergic inflammation and increased levels CCL17 have been found in plasma and BALF from asthmatic patients (40). A variety of different cell types have been shown to produce CCL17 including structural cells, such as bronchial epithelial cells, and several leukocyte populations, such as T cells, dendritic cells and macrophages. Several reported have demonstrated that IL-4 induced CCL17 production from monocytes and macrophages (41, 42). And although it has been suggested that CCL17 is a marker of alternative macrophage activation, other work has suggested that they function more to recruit cells to the site of inflammation (43). CCL17, as well as CCL22, signal via the CCR4 receptor and recent studies have demonstrated that targeting CCR4 resulted in reduced AHR and controlled allergic airway inflammation (44, 45). Although there was a significant increase in the mRNA expression of CCR4 in macrophages isolated from the lung after DRA challenge, there was no difference in the upregulation of CCR4 in Sirt2 Tg mice compared to Sirt2 WT mice. Taken together, these data demonstrate an important role for CCL17 in regulating macrophage activation as well as allergic inflammation in the lung.

Previous work has demonstrated that epigenetic changes contribute to the development of allergic asthmatic inflammation (46). Sirtuins are a class of proteins that possess mono-ADP-ribosyltransferase activity and are considered a histone deacetylase (HDAC) capable of epigenetic modification. Several classes of sirtuin have been characterized by subcellular localization, enzymatic activity, and function (47). Our work focuses on the role of Sirt2, which is a member for the Class I sirtuins that have been
shown to be key modulators of cell signaling processes involved in homeostatic regulation, cell division, cell death and production of defense mechanisms. In particular, it has previously been shown that the pan-class I sirtuin inhibitor, sirtunol, was effective in reversing allergic inflammation in murine model of OVA exposure (48). While the role of Sirt2 has not been investigated previously during allergic asthmatic inflammation, treatment of mice with the Sirt2 inhibitor AGK2 in the setting of experimental sepsis and occlusive cerebrovascular ischemia resulted in both a survival and anti-inflammatory benefit (49-51). In contrast to the pan-Class I Sirt inhibitors, previous work has demonstrated that AGK2 is highly specific for Sirt2. AGK2 has a calculated IC50 for Sirt2 of 3.5 μM and only slightly inhibits Sirt1 and Sirt3 at concentrations over 40 μM (26). Together, these data suggest that upregulation of Sirt2 could be a necessary mechanism by which allergic inflammation occurs.

A structural analysis of Sirt2 indicates that it contains a NAD-binding domain and a catalytic domain with deacetylase activity (52). Initially, of the different Sirt2 variants, Sirt2 isoform 1 and 2 both contain a nuclear export signal (NES) have been the best characterized and predominantly localize to the cytoplasm (18). Although a predicted Sirt2 isoform 4 variant is in the GenBank database, the predicted protein structure and functionality of this isoform have yet to be determined. Several groups have identified a third variant of Sirt2, which has been referred to as isoform 3, found in mice and rats, (23, 25) as well as isoform 5, found in humans (24). Because we examine expression of the Sirt2 isoforms using both human and murine samples, we have chosen to refer to the third isoform as Sirt2 isoform 3/5. Our data show that in vivo exposure to allergen and in vitro treatment with IL-4 increases Sirt2 isoform 3/5 in lung macrophages. Based on our data, we hypothesize that Sirt2 isoform 3/5 is the IL-4 dependent variant which regulates allergic inflammation. The mechanism by which Sirt2 isoform 3/5 regulates this responses is somewhat perplexing since it does not contain a nuclear export sequence and is therefore stuck in the nucleus and initial reports failed to demonstrate in vitro catalytic activity despite an intact catalytic domain (24). It is known that nuclear Sirt2 has specific histone H3K18 deacetylation activity (53) and recently, it has been shown that Sirt2 has increased enzymatic activity when incubated with nucleosomal-linked substrates over naked protein (54). This is an important finding because previous
work has demonstrated that cytoplasmic Sirt2 functions during mitosis as a tubulin deacetylase (18, 55, 56), whereas nuclear Sirt2 has specific HDAC activity (52, 53) for Histone 3 and Histone 4 (H3/H4) when engaged with an acetylated nucleosome (54). Additional work to determine the target and mechanism by which IL-4 stimulated Sirt2 isoform 3/5 can regulate macrophage activation in the setting of allergic inflammation is an area of ongoing research in our laboratory.

Taken together, these results demonstrate that Sirt2 isoform 3/5 influences the development of experimental allergic asthmatic inflammation. Our data show a novel mechanism by which expression of a histone deacetylase, Sirt2, regulates the production of CCL17 and recruitment of myeloid-derived cells into the lung following sensitization and challenge with DRA. Using both pharmacologic inhibitors and genetic manipulation, we demonstrate changes in cellular composition and airway resistance. We believe that these data can have direct implications to human allergic airway disease because we demonstrate similarities between in Sirt2 isoform 3/5 expression in both primary mouse and human lung macrophages after in vitro IL-4 stimulation. In summary, our findings provide additional support for the growing hypothesis that macrophage activation regulates the development of allergic inflammation.
Methods:

Mice:
The transgenic Sirt2 overexpressing (Sirt2 Tg) mice and Sirt2 knockout mice (Sirt2 KO) were kindly gifted by Dr. Fen Xia (The Ohio State University, Columbus, Ohio). The wild-type C57BL/6 mice were commercially sourced (Jackson) WT. Male and female mice were used at age of 8–12 weeks in this study.

Allergic inflammation model and Sirt2 inhibition in vivo:
The allergic asthma model was performed as previously described (12, 57). The triple-allergen mixture was composed of extracts of dust mite (Dermatophagoides farina), ragweed (Ambrosia artemisiifolia), and Aspergillus fumigatus (DRA; Greer Laboratories, Lenoir, NC). Briefly, on days 0 and 5, mice were intraperitoneally (i.p.) sensitized with the DRA allergen mixture (5 μg of dust mite, 50 μg ragweed, and 5 μg Aspergillus fumigatus) in 200 μl of alum as an adjuvant (Imject, Alum; Thermo Scientific). Mice were then intranasally (i.n.) challenged with 50 μL of saline or DRA (8.3 μg dust mite, 83.4 μg ragweed, and 8.3 μg Aspergillus fumigatus) on days 12, 13, and 14. Control mice were sensitized as above, but were i.n. challenged with saline in place of DRA. Mice were sacrificed on day 15, and bronchoalveolar lavage (BAL) fluid and lung tissues were collected for further analysis. AGK2 (10 mg/kg) was administered i.p. with 2% of tween20 and 10% of PEG-400 in PBS 30 min prior to DRA challenge at day 12, 13 and 14. Timeline of the DRA and AGK2 administration is shown in Supplemental Figure 1A.

BAL differential cell count:
BAL fluid was collected as previously described (12, 57). Briefly, airways were lavaged with PBS and 0.6mM EDTA and analyzed for total cell counts using the Countess automated cell counter (Life Technologies). Cells isolated from the BALF were stained with HEMA 3 (Thermo Scientific) and the number of macrophages and eosinophils was quantitated by microscopy.
**Measurement of cytokines:**

The Proteome Profiler™ mouse cytokine array panel A (R&D systems) was used to detect cytokine expression profile in mouse BAL fluid. In addition, BAL fluid and cytokine secretion in culture supernatants was analyzed by ELISA specific for mouse CCL17 (R&D systems) following the protocols supplied by the manufacture.

**Isolation of macrophages:**

Macrophages were isolated from the whole lungs of mice via a collagenase digestion, as previously described (58). Cells were adherence purified for 30 min in serum-free media, non-adherent cells (such as lymphocytes) were washed away, and complete media was replaced for overnight incubation. Lung macrophages were incubated in the presence or absence of rmIL-4 (20 ng/ml). Mouse bone marrow cells were isolated from the femurs and tibias of mice and incubated with rmM-CSF for 7 days in order to differentiate bone marrow-derived macrophage (BMDM) (59). Peritoneal macrophages were isolated from the peritoneal cavity and adherence purified before use.

**Lung histology and airway mucus expression:**

Mouse lung tissue was prepared using pressurized low-melting agarose as described previously (7). Briefly, low-melting-point agarose was infused through the tracheostomy then the tube was tied, the lung removed, and placed into 10% formalin. Both hematoxylin and eosin (H&E) staining and periodic acid-Schiff (PAS) staining were conducted by the Comparative Pathology and Mouse Phenotyping Shared Resource at the Ohio State University. Whole lung images were analyzed by Aperio or Gen5 software.

**Measurements of airway hyper responsiveness:**

Mice were anesthetized with pentobarbital (100 mg/kg; i.p.), and pancuronium bromide was administered (0.8ml/kg; i.p), and a tracheostomy tube was inserted. Mechanical ventilation was initiated using a Flexivent small animal ventilator (Sireq, Montreal, QC). Continuous EKG and pulse oximetry monitoring
was performed. Airway resistance was measured after sequentially increasing doses of aerosolized methacholine using the FlexiVent system as described previously (60).

**Western blot analysis:**

Cells were lysed in RIPA buffer (Millipore, Temecula, CA) in the presence of protease inhibitor (Cell Signaling Technology, Danvers, MA). Cell lysates containing equal amounts of protein were electrophoresed and immunoblotted using the following antibodies: Sirt2 (C-term, Sigma-Aldrich), β-actin (Cell Signaling; 8H10D10) and histidine tag (AbD Serotec; AD1.1.10) and all secondary antibodies were purchased from Cell Signaling.

**Sirt2 overexpression vectors and transfections:**

Sirt2-isoform 1 and isoform 5 plasmid vectors were generated by Dr. Marthias Ziegler (University of Bergen, Gerben, Norway) (24). HEK 293 cells were transfected with pcDNA3.1/V5-His-Sirt2-Isoform1 or Isoform5 by Lipofectamine 3000 for 3hr and harvested at 48 hr. Expression of isoform1 and 5 was confirmed with anti-His and anti–Sirt2 C-terminal antibodies by immunoblotting.

**Flow cytometry:**

Cells collected from BAL fluid or isolated from collagenase digestion of lungs were fixed with 2% PFA for flow cytometric analysis. Cells incubated with Fc blocking anti-mouse CD16/32 antibody (BD Bioscience; 2.4G2) followed by antibodies against pan-CD45 (BioLegend; 30-F11), CD45.1 (BioLegend; A20), CD45.2 (BioLegend;104), CD11c (BioLegend; N418), CD11b (BioLegend; M1/70), CD3 (e Bioscience; 14A2 and 145-2C11), Ly6G (BioLegend; 1A8), and Siglec F (BS Biosciences; E50-2440). Cells were analyzed on a BD LSR II (BD Bioscience) where gating was based on respective unstained cell population and isotype matching control antibodies. The data were analyzed with FlowJo software (TreeStar). Flow cytometric gating scheme is presented in Supplemental Figure 2.
**Bone marrow transplantation:**

Mice received 13 Gy total body irradiation delivered in two fractions separated by 3 hr as previously described (58). Bone marrow was harvested from the femurs of donor mice, and bone marrow was transplanted into the lethally irradiated recipients via tail vein infusion. All experiments with bone marrow transplantation mice were performed 6 wk after bone marrow transplantation and complete reconstitution was determined by measuring donor versus recipient cells (Supplemental figure 2). Total lung cells were isolated by collagenase digestion from the right lobes and BAL fluid was collected from left lobe and whole lung tissue was collected for cell isolation and histological samples.

**Adoptive transfer experiments:**

CD45.1 mice were sensitized by DRA and alum at day 0 and 5. WT or Tg mouse lung macrophages were isolated as described above and adherence purified for 1 hr in serum-free media. The adherent cells were collected using 0.05% trypsin, and the percentage of live cells was quantified. Cells were resuspended at a concentration of 4 x 10^6 cells in 50 µL of PBS, and then then transferred to the sensitized CD45.1 mice i.n. at day 8.

**RNA extraction and qPCR:**

RNA was extracted from cells or lung tissues homogenates by using a Direct-zol RNA miniPrep Plus Kit (Zymo Research) according to the manufacture’s instruction. cDNA synthesis was performed using the RevertAid First Strand cDNA Synthesis Kit (Thermo) and gene expression was measured by quantitative PCR in an Roche LightCycler 480 (Roche), and data were analyzed by the 2^{ΔΔCt} method with GAPDH expression as an endogenous control.

**Human cells:**

Alveolar macrophages were isolated via ex vivo BAL by instilling PBS and 0.6mM EDTA into the airways of the lungs and then removing the lavage fluid by suction. Cells were adherence purified by
incubating for 1 hr in serum-free media and overall macrophage purity was >95% as determined by modified Wright-Giemsa staining. Cells were either utilized immediately or stimulated with rhIL-4 (20 ng/ml), rhIL-13 (20 ng/ml) and rhIFNγ (20 ng/ml) to induce macrophage activation.

Statistics:
Data were expressed as mean ± SEM. Differences between groups of mice were evaluated with two-way ANOVA between indicated groups. Student's two-tailed t-test was used for other analyses. The statistical software Sigmaplot 12.0 was used for the analysis. P-value <0.05 was considered statistically significant.

Study approval:
All experiments involving mice were conducted with protocols approved by the Institutional Animal Care and Use Committee (IACUC) of The Ohio State University. Human cells were isolated from lungs deemed not viable for transplantation based on a panel of specific donor characteristics. These lungs were procured from LifeLine of Ohio (LOOP), which is the organ procurement agency in central Ohio.
**Author contributions:**

Designing research studies (YGL, JAE, MZ, GYP, JWC, MNB) conducting research studies (YGL, BFR, DH, AS, SC, MK, MNB), acquiring data (YGL, BFR, DH, AS, SC, MK) analyzing data (YGL, DH, AS, JAE, GYP, JWC, MNB), providing reagents (MZ, GYP), and writing the manuscript (YGL, JAE, JWC, MNB).
Acknowledgements: We would like to thank analytical flow cytometry core (P30CA016058) for their technical assistance and the Davis Heart and Lung Research Institute.
References:


**Figure 1** Sirt2 regulates allergic inflammation following DRA challenge. WT, Sirt2 over-expression (Tg) or Sirt2 deficient (KO) mice were DRA sensitized and challenged. (A) The total number of cells and cell differentials from BAL fluid after DRA as determined by cytospin analysis n=5 mice/group and analyzed by one-way ANOVA. (B) Whole lung histological sections were stained for PAS (Periodic acid-Schiff) to determine goblet cell hyperplasia. Representative image with a 2 mm scale bar on the top images and a 200 µm scale bar on the bottom images repeated 5 times. (C) Airway resistance was measured using increasing doses of methacholine in WT and Tg mice after DRA challenge n=5 mice/group and analyzed 2way ANOVA. (D) CCL7 ELISA with n=5/group analyzed by one-way ANOVA. (E) Lung macrophages from WT or Tg mice were isolated and expression of Sirt2 isoforms were detected with either N-term or C-term specific antibodies at time 0 and after a 48 hr incubation in the presence or absence of rmIL-4 (20 ng/ml). 3 mice combined per group, representative blot performed 3 times. *p<0.05, **p<0.01, ****p<0.001 when compared to WT controls and ### p<0.001 when compared within the groups.
Figure 2. Administration of AGK2, a selective Sirt2 inhibitor, attenuates allergic inflammation by modulating alternative activation of macrophages and CCL17 production. AGK2 (10 mg/kg; i.p.) was administered 30 min prior to DRA challenge on day 12, 13 and 14. (A) Total lung cells were labeled with surface markers for CD45, CD3, CD11c, CD11b, Ly6G and SiglecF, gated on CD45+ cells and the percentage of eosinophils, alveolar macrophages, monocytes/interstitial macrophages, T cells, and neutrophils were determined n=5 mice/group and analyzed by one-way ANOVA. (B) Whole lung histological sections were PAS stained. Representative image with a scale bar measuring 3 mm in top insert at and a scale bar measuring 200 µm in the bottom insert repeated 5 times. (C). CCL17 production in BAL fluid was measured by ELISA n=5 mice/group and analyzed by one-way ANOVA. (D). Alternative activation macrophage markers were assessed in whole lung tissue after DRA-challenge by qPCR n=5 mice/group and analyzed by one-way ANOVA. (E). Lung macrophages were isolated from WT mice and incubated with rmIL-4 (20 ng/ml) for 24hr in the presence of AGK2 and expression of CCL17 and alternative activation markers were assessed by qPCR n=3 mice/group and analyzed by one-way ANOVA. *p<0.05, and **** p<0.001 when compared to WT control. #p<0.05, ###p<0.001, and #### p<0.0001 when compared within the groups.
Figure 3. Bone marrow-derived cells overexpressing Sirt2 enhances susceptibility to DRA-challenge allergic inflammation.
Bone marrow chimeras were generated by transplanting WT or Tg Sirt2 bone marrow cells (CD45.2) into lethally-irradiated CD45.1 mice. After completion of bone marrow reconstitution (6 weeks), mice were sensitized and challenged. The left lung tissue was isolated for histology and lung cells from right lobes were isolated via collagenase digestion. (A) Total number of CD45.2 cells was quantified in the lung tissue n=4 mice/group analyzed by one-way ANOVA. (B) Cellularity of the BAL was determined by flow cytometric staining and graphed as percentage of donor-derived CD45.2 cells n=4 mice/group analyzed by one-way ANOVA. (C) Whole lung histological sections were PAS stained. Representative image with a 2 mm scale bar on the left, a with top insert with a 1 mm scale bar and the bottom insert with a 200 µM scale bar repeated 4 times. (D) Production of CCL17 was assessed in BAL fluid by ELISA n=4 mice/group analyzed by unpaired t-test. *p<0.05, **p<0.01 and ****p<0.005 when compared to WT control and ### p<0.001 when compared within the groups.
Figure 4. Adoptive transfer of Sirt2 transgenic overexpressing lung macrophage exacerbates DRA-challenge.
Lung macrophages from WT or Tg Sirt2 mice were transferred i.n. into sensitized CD45.1 mice on day 8. Both groups of mice were then challenged with DRA on day 12 to 14. On day 15, left lung tissue was isolated for histology and lung cells from right lobes were isolated via collagenase digestion. (A) Relative percentages of different subpopulations of lung immunological cells were assessed by flow cytometry as described in supplemental figure 2. The number of cells were quantified based on the number of recipient CD45.1+ cells n=5 mice/group analyzed by one-way ANOVA. (B) Lung histological slides were stained with PAS to determine goblet cell hyperplasia. Representative image with a 2 mm scale bar on the left, a with top insert with a 1 mm scale bar and the bottom insert with a 200 µM scale bar repeated 5 times. (C) Expression of CCL17 was assessed in whole lung tissue by qPCR and production of CCL17 in BAL fluid was measured by ELISA n=5 mice/group analyzed by one-way ANOVA. (D) Expression of markers of alternatively activated macrophages, Fizz1 and YM1, was determined in lung tissue after DRA-challenge was assessed by qPCR n=5 mice/group analyzed by one-way ANOVA. ****p<0.001 and **p<0.01.
Figure 5. Sirt2 plays important role on alternative macrophage activation and CCL17 expression.
Primary human alveolar macrophages were isolated via ex vivo lavage from healthy donors. (A) Alveolar macrophages were stimulated with IL-4, IL-13 or IFNγ for 48hr and expression of Sirt2 isoforms were detected with either N-terminus or C-terminus specific antibodies. Blot represents 1 set of patient samples, but performed on 3 separate patients. (B) Human AMs macrophages were incubated with rhIL-4 (20 ng/ml) for 24hr in the presence of AGK2 and expression of CCL17 and (C) alternative activation macrophage markers Arg1 and MRC1 were assessed by qPCR n=3 samples/group analyzed by one-way ANOVA. *p<0.05, **p<0.01, and ***p<0.001 when compared to untreated. #p<0.05 and ##p<0.01 and ####p<0.001 when compared across groups.